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SHORT COMMUNICATION
Abstract
Despite recent advances in acute heart failure treat-
ment, actual results remain limited in refractory cardio-
genic shock. Temporary ventricular assist devices have 
emerged as an alternative in this serious and challenging 
medical. The purpose of this communication is to present a 
case of refractory cardiogenic shock, underwent temporary 
left ventricular assistance device implantation, progressing 
to right ventricular failure and conversion to biventricular 
support.
Descriptors: Shock, cardiogenic. Ventricular dysfunction, 
right. Ventricular dysfunction, left.
Resumo
Apesar dos avanços no tratamento de portadores de insuficiên-
cia cardíaca aguda, os resultados permanecem insatisfatórios nos 
portadores de choque cardiogênico refratário. Uma opção para o 
tratamento dessa desafiadora e grave situação clínica é o implante 
de dispositivos de assistência ventricular temporária. O objetivo 
desta comunicação é apresentar um caso de choque cardiogênico 
refratário, com indicação de assistência ventricular, que evoluiu 
com falência ventricular direita após o implante de assistência es-
querda com necessidade de conversão para o suporte biventricular.
Descritores: Choque cardiogênico. Disfunção ventricular di-
reita. Disfunção ventricular esquerda.
INTRODUCTION
Despite recent advances in the treatment of acute heart 
failure, results remain unsatisfactory for patients with 
refractory cardiogenic shock. These patients are often 
referred to specialized centers when it is too late, which 
leads to adverse results. Temporary ventricular assist devices 
offer an alternative for the treatment of this serious and 
challenging medical issue.  Although there are still some 
doubts about the ideal type of assistance, the length of stay of 
the device, and the best time to start long-term treatment, this 
technology should be more employed and disseminated [1]. 
Initially, these devices were used in case of heart failure after 
the removal of cardiopulmonary bypass during open heart 
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left ventricular function (ejection fraction of 16%), with mild 
to moderate right ventricular dysfunction. 
After discussing the refractory cardiogenic shock 
diagnosis with several experts, the recommended procedure 
was emergency temporary left ventricular assist device 
implantation, with the Levitronix CentriMag (VAS)® 
device. The procedure was performed with normothermic 
cardiopulmonary bypass (CPB), without aortic clamping. 
Suitable cannulas were inserted at the left ventricle apex and 
ascending aorta. After the removal of CPB, the device was set 
for 3200 rotations per minute (RPM) with a flow of 4.5 L/min/
m² and continuous infusion of vasoactive drugs. Postoperative 
hemodynamic conditions were improved, with the return 
of diuresis (approximately 1 ml/Kg/hour), venous oxygen 
saturation of 75%, and serum lactate of 22 mmol/L. Six hours 
after the procedure, the patient was awake and had neither 
neurological deficits nor bleeding from coagulopathy. 
Abbreviations, acronyms & symbols
CI Cardiac index 
CO Cardiac output 
CPB Cardiopulmonary bypass 
RV Right ventricle
surgery; however, their use has changed and spread to other 
kinds of therapy, such as support therapy for patients waiting 
for a heart transplant or as a choice of destination therapy. 
The Levitronix CentriMag (Levitronix LLC, Waltham, 
Mass) - Ventricular Assist System (VAS)® device has been 
especially designed for the treatment of patients with acute 
cardiogenic shock of any kind, including: acute myocardial 
infarction, myocarditis, postcardiotomy, and complications 
after procedures carried out in the hemodynamic laboratory. It 
can be used for the support of the left or right ventricles as well 
as for biventricular support. In addition, since its handling and 
implantation are considered easy, the device can even be used 
in centers where prolonged ventricular assistance programs 
and heart transplants are not available [2].
Several authors have established an increase in mortality 
of patients with right ventricular dysfunction after they were 
treated with these devices. They concluded there is a need 
to identify factors predictive of right ventricular failure after 
left ventricular assist device implant, making it possible to 
decide for biventricular implantation preoperatively [3].
The purpose of this communication is to present a case of 
refractory cardiogenic shock, in which the patient underwent 
left ventricular assist device implantation, progressing 
to right ventricular failure, and subsequent conversion to 
biventricular support.
CLINICAL CASE
A 36-year-old male was admitted to the Intensive Care 
Unit after a two-week stay at another hospital with clinical, 
hemodynamic, and echocardiographic picture suggestive of 
severe refractory cardiogenic shock (he was using more than 
one vasoactive drug at optimized doses). The patient had had 
viral myocarditis two years before and had been suffering 
from progressive dyspnea, which had worsened in the 
previous six months. A month before being admitted, there 
was intensive worsening with dyspnea at rest, orthopnea, 
paroxysmal nocturnal dyspnea, and anasarca. 
Upon admittance, hemodynamic monitoring was 
performed through the insertion of a Swan-Ganz catheter, 
with the following parameters: cardiac index (CI) at 1.3 
L/min/m², cardiac output (CO) at 2.5 L/min, right atrium 
pressure at 18 mmHg, pulmonary artery pressure at 66x30 
mmHg, and pulmonary capillary pressure at 23 mmHg. The 
chest radiograph can be seen in Figure 1. The two-dimensional 
transthoracic echocardiography showed severely impaired 
Fig. 1 – Chest radiograph
However, after 12 postoperative hours, there was 
substantial reduction in urine volume, increase in the right 
atrium pressure, and decrease in the pulmonary artery pressure. 
The right ventricular failure diagnosis was corroborated 
by the echocardiography, which showed there was a sharp 
decrease in right ventricular contractility. Consequently, 
the patient was once again taken to the operating room for 
right ventricular assist implantation, with pulmonary artery 
and right atrium cannulation, without CPB (Figure 2). Once 
appropriate flows were established (kept at 10% less on the 
right side), the patient was taken to the postoperative unit. 
Even though the biventricular assist device and the optimized 
vasoactive drugs were working properly, evolution was 
unsatisfactory with the development of anuria and a hard 
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to control coagulopathy (liver failure), leading to death 38 
hours after the procedure. 
The indication of the procedure was carried out according 
to ethical principles. Both the patient and his relatives agreed 
to the procedure and signed the informed consent form 
provided by the hospital.
avoiding multiple organ failure by re-establishing systemic 
perfusion. Preoperative laboratory evaluations did not reveal 
any alterations in liver and kidney function parameters, nor 
thrombocytopenia, underscoring the need for immediate 
support. 
The choice of this device was based on its versatility, 
mono- or biventricular support, and the possibility of 
interposition of oxygenator for ventilatory support, if 
needed. Moreover, the device could be used for several 
weeks until destination therapy was chosen and cannulas that 
were exteriorized in the chest could be used for a long-term 
device. After a multidisciplinary discussion, it was decided 
a long-term device would be a better option than ECMO 
(Extracorporeal membrane oxygenation) considering that, 
currently, it takes a long time for a heart to be available for 
transplant. 
Despite the great technological advances of these 
devices, mortality in this group of patients remains high due 
to complications such as infection, bleeding, and embolism 
[3]. In 2011, a multicenter study with the CentriMag (VAS)® 
device described the effectiveness of the pump in emptying 
both ventricles and acting as a biventricular circulatory 
support in cases of cardiogenic shock. Overall mortality was 
47% out of 38 patients and the benefits of using the device 
included: easy handling and implantation, low incidence of 
complications related to the device, and support until final 
course of treatment [1]. In 2012, the results of the use of 
Centrimag (VAS)® in 12 patients with cardiogenic shock and 
multiple organ dysfunction, published by John et al., showed 
overall survival of 75% thirty days after the implantation [4].
In the present case, the ease of both handling and 
implantation of the Centrimag (VAS)® device was confirmed; 
however, right ventricular failure was considered a major 
factor in the adverse development which culminated in the 
employment of biventricular support. Although the initial 
intention was the immediate implantation of the biventricular 
device, it was decided not to do so because of the hemodynamic 
conditions after left ventricular support implantation (after 
removal of CPB, it was noted there was improvement in 
right ventricular contractility, as confirmed by clinical, 
hemodynamic, and echocardiography parameters). It seems 
essential to predict right ventricular failure. Fitzpatrick et al. 
[5] have shown that the conversion from left to biventricular 
support have worse results when compared to an insertion 
that had been previously indicated and performed at the same 
time. Furthermore, the authors demonstrated that despite a 
higher mortality in the biventricular support group, survival 
rate after transplant is the same in both groups (mono- or 
biventricular). 
After reviewing the case, it became apparent the decision 
not to implant the biventricular support may have influenced 
the evolution, considering the subsequent conversion to 
the biventricular system. For this reason, in another related 
Fig. 2 – A – Right atrium cannula; B – Ascending aorta cannula; 
C – Pulmonary artery cannula
DISCUSSION
Temporary assist devices are used as rescue therapy in 
order to re-establish hemodynamic conditions and avoid 
multiple organ failure, until a decision is made regarding 
whether to have prolonged assistance or a heart transplant. It 
is important to note that clinical and hemodynamic criteria are 
used in the selection of candidates for mechanical circulatory 
support devices implantation. Some of the important clinical 
factors taken into consideration are: age (65 to 70 years-old), 
refractory cardiogenic shock due to the use of vasoactive 
drugs in high doses combined with persistent hypotension, 
and preoperative factors associated with poor prognosis 
(acute liver or renal failure, cerebrovascular disease, active 
infectious process, and thrombocytopenia). Hemodynamic 
factors are important for the likely identification of right, left, 
and/or biventricular failure, and are obtained by determining 
cardiac index, right atrium pressure, pulmonary capillary 
pressure, and systolic arterial pressure. 
In the case being presented in this communication, the 
fact the patient was young was taken into consideration. In 
addition, despite the severity of the hemodynamic conditions 
at the time of admittance, no clinical criteria that would 
prevent a circulatory support device implantation were 
identified. On the contrary, there was the potential benefit of 
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publication, Fitzpatrick et al. [6]   showed the main factors 
involved in right ventricular failure are: cardiac index (below 
2.2 L/min/m²), right ventricular (RV) systolic work index 
(below 0.25 mmHg), severe preoperative RV dysfunction, 
higher levels of plasma creatinine (above de 1.9 mg/dL), 
previous cardiac surgery, and systolic arterial pressure below 
96 mmHg.
There have been many advances in the treatment of 
patients with chronic heart failure; however, in cases of 
severe cardiogenic shock, results are still below expectations. 
Many times, unfavorable results are related to unavailability 
of mechanical ventricular support as well as the critical 
conditions of patients referred to specialized centers. In 
the case presented in this communication, the need for 
biventricular support after the mono-ventricular implantation 
was highlighted as a complicating factor.
